Vertex Pharmaceuticals Inc. (VRTX)

176.14
2.55 1.47
NASDAQ : Health Technology
Prev Close 173.59
Open 174.36
Day Low/High 174.02 / 176.98
52 Wk Low/High 151.80 / 195.81
Volume 738.87K
Avg Volume 1.18M
Exchange NASDAQ
Shares Outstanding 257.04M
Market Cap 44.32B
EPS 8.20
P/E Ratio 20.19
Div & Yield N.A. (N.A)
Vertex Pharma Cystic Fibrosis FDA Advisory Panel Live Blog

Vertex Pharma Cystic Fibrosis FDA Advisory Panel Live Blog

A group of outside experts convened by the U.S. Food and Drug Administration is meeting Tuesday to review a new combination therapy for cystic fibrosis developed by Vertex Pharmaceuticals.

3 Fantastic Pharmaceutical Stocks: Abbvie, Vertex and Biogen

3 Fantastic Pharmaceutical Stocks: Abbvie, Vertex and Biogen

AbbVie is a cheap stock and worries about competition immediately hurting its rheumatoid arthritis drug Humira are overblown, said John Schroer, Portfolio Manager for the AllianzGI Health Sciences Fund.

Today's Pre-Market Laggard Is Vertex Pharmaceuticals (VRTX)

Today's Pre-Market Laggard Is Vertex Pharmaceuticals (VRTX)

Trade-Ideas LLC identified Vertex Pharmaceuticals (VRTX) as a pre-market laggard candidate

3 Stocks Raising The Drugs Industry Higher

3 Stocks Raising The Drugs Industry Higher

TheStreet highlights 3 stocks pushing the drugs industry higher today.

Vertex Pharmaceuticals Becomes #232 Most Shorted S&P 500 Component, Replacing Fidelity National Information Services

Vertex Pharmaceuticals Becomes #232 Most Shorted S&P 500 Component, Replacing Fidelity National Information Services

The most recent short interest data has been released by the NASDAQ for the 04/15/2015 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Biotech Stock Mailbag: Biotech Bull So Insanely Good It Will Make You Forget Week's Pain

Biotech Stock Mailbag: Biotech Bull So Insanely Good It Will Make You Forget Week's Pain

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Vertex Reports First Quarter 2015 Financial Results

Vertex Reports First Quarter 2015 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended March 31, 2015.

Earnings and Marriage Season

Biotech companies are saying, "I do."

Dow Extends Losses; Travelers Falls After Missing Earnings Estimates

Dow Extends Losses; Travelers Falls After Missing Earnings Estimates

Stocks are mixed on Tuesday as disappointing earnings drag on overall markets.

Stick With Mylan Laboratories, Whether Teva Buys It or Not

Stick With Mylan Laboratories, Whether Teva Buys It or Not

Mylan will generate a higher stock price for its shareholders in the coming months, deal or no deal.

Deal or No Deal, Stick With Mylan

Teva bid highlights M&A action in health care sector.

Deal or No Deal, Stick With Mylan

Deal or No Deal, Stick With Mylan

Teva bid highlights M&A action in health care sector.

Stocks Are Mixed as DuPont and Verizon Drag on the Dow

Stocks Are Mixed as DuPont and Verizon Drag on the Dow

Stocks are mixed on Tuesday as disappointing earnings from several large-caps overshadow a global rally.

Strong On High Relative Volume: Vertex Pharmaceuticals (VRTX)

Strong On High Relative Volume: Vertex Pharmaceuticals (VRTX)

Trade-Ideas LLC identified Vertex Pharmaceuticals (VRTX) as a strong on high relative volume candidate

Gilead Should Buy Vertex Pharma for $45B Now, Analyst Says

Gilead Should Buy Vertex Pharma for $45B Now, Analyst Says

Gilead Sciences should solve its long-term revenue cliff problem by acquiring Vertex Pharmaceuticals and its growing cystic fibrosis drug franchise for $45 billion, says Bernstein analyst Geoff Porges.

Vertex To Announce First Quarter 2015 Financial Results On April 29

Vertex To Announce First Quarter 2015 Financial Results On April 29

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2015 financial results on Wednesday, April 29, 2015 after the financial markets close.

Deutsche Compares PTC Therapeutics To Vertex, Boosts Target By $40

Deutsche Compares PTC Therapeutics To Vertex, Boosts Target By $40

Shares of PTC Therapeutics are rising this morning after Deutsche Bank compared the company's earnings power potential to another drugmaker, Vertex, and raised its price target on PTC shares.

Mylan Deal the Rx for Drug Stocks

Even the second-tier biotechs are taking off.

These 10 Pharma and Health Care Stocks Were the Worst S&P 500 Performers Last Quarter

These 10 Pharma and Health Care Stocks Were the Worst S&P 500 Performers Last Quarter

Some of the biggest pharmaceuticals companies were some of the health care sector's worst performers in the first quarter.

Stocks Finish Lower for the Week as Fed Talk Spooks Investors

Stocks Finish Lower for the Week as Fed Talk Spooks Investors

Wall Street ends its four-day losing streak on Friday, but the minor gains are nowhere near enough to erase big losses suffered over the week.

Stock Markets Hold Onto Slight Gains Ahead of Yellen Speech

Stock Markets Hold Onto Slight Gains Ahead of Yellen Speech

Stocks inch higher on Friday afternoon, recovering from an earlier drop.

Stocks Climb, Nasdaq Leads Markets as Health Care Rebounds

Stocks Climb, Nasdaq Leads Markets as Health Care Rebounds

Stocks rose slightly on Tuesday.

Stocks Slump at the Close as Dollar's Decline Fails to Ignite Rally

Stocks Slump at the Close as Dollar's Decline Fails to Ignite Rally

Markets tried for gains on Monday, but struggled for much of the day even as the dollar's decline gave extra impetus to a rally.

Stocks Mixed as Fed's Fischer Says a Rate Hike is Likely This Year

Stocks Mixed as Fed's Fischer Says a Rate Hike is Likely This Year

Stocks are modestly higher by late morning Monday as the continued decline in the U.S. dollar boosts crude prices.

11 Promising New Drugs Expected to Make Billions in Sales

11 Promising New Drugs Expected to Make Billions in Sales

Big pharmaceuticals companies are expected to unveil lots of promising drug therapies in 2015 - specifically drugs that could make billions in sales within five years.

Vertex Pharmaceuticals (VRTX) Stock Falls Today on Cystic Fibrosis Drug Trial Data

Vertex Pharmaceuticals (VRTX) Stock Falls Today on Cystic Fibrosis Drug Trial Data

Shares of Vertex Pharmaceuticals (VRTX) were down in morning trading Monday after the company announced its cystic fibrosis drug Kalydeco came up short of analysts' expectations in a mid-stage trial.

Vertex Cystic-Fibrosis Drug Smacked by Burden of High Expectations

Vertex Cystic-Fibrosis Drug Smacked by Burden of High Expectations

Vertex disclosed some new phase IIb study results that raise concerns VX-661 may not be as potent as previously hoped.

Vertex Announces Data From 12-Week Phase 2 Safety Study Of VX-661 In Combination With Ivacaftor In People With Cystic Fibrosis Who Have Two Copies Of The F508del Mutation

Vertex Announces Data From 12-Week Phase 2 Safety Study Of VX-661 In Combination With Ivacaftor In People With Cystic Fibrosis Who Have Two Copies Of The F508del Mutation

Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced data from a 12-week Phase 2 study evaluating VX-661 in combination with ivacaftor in 39 people with CF ages 18 and older who have two copies of the...

The 7 Pillars of Healthcare Strength

Here are healthcare stocks of all shares and sizes with strong charts.

Vertex Pharmaceuticals (VRTX) Hits New Lifetime High Today

Vertex Pharmaceuticals (VRTX) Hits New Lifetime High Today

Trade-Ideas LLC identified Vertex Pharmaceuticals (VRTX) as a new lifetime high candidate

TheStreet Quant Rating: B (Buy)